The trajectory of Viagra presents a nuanced case for observers in the pharmaceutical sector. While initially a tremendous success, creating billions, the exclusivity expiration and the subsequent flood of off-brand versions have considerably affected earnings. This presents questions about the long-term sustainability of analogous therapeutic devel